Your browser doesn't support javascript.
loading
Erythropoietin Attenuates Postoperative Cognitive Dysfunction by Shifting Macrophage Activation toward the M2 Phenotype.
Lee, Jae Hoon; Kam, Eun Hee; Kim, So Yeon; Cheon, So Yeong; Kim, Eun Jung; Chung, Seungsoo; Jeong, Ji-Hyun; Koo, Bon-Nyeo.
Afiliación
  • Lee JH; Department of Anesthesiology and Pain Medicine, Severance Hospital, Seoul, South Korea.
  • Kam EH; Anesthesia and Pain Research Institute, College of Medicine, Yonsei University, Seoul, South Korea.
  • Kim SY; Anesthesia and Pain Research Institute, College of Medicine, Yonsei University, Seoul, South Korea.
  • Cheon SY; Department of Anesthesiology and Pain Medicine, Severance Hospital, Seoul, South Korea.
  • Kim EJ; Anesthesia and Pain Research Institute, College of Medicine, Yonsei University, Seoul, South Korea.
  • Chung S; Anesthesia and Pain Research Institute, College of Medicine, Yonsei University, Seoul, South Korea.
  • Jeong JH; Department of Anesthesiology and Pain Medicine, Severance Hospital, Seoul, South Korea.
  • Koo BN; Anesthesia and Pain Research Institute, College of Medicine, Yonsei University, Seoul, South Korea.
Front Pharmacol ; 8: 839, 2017.
Article en En | MEDLINE | ID: mdl-29201007
ABSTRACT
Postoperative cognitive dysfunction (POCD) may be driven by transference of the innate immune response to the brain after aseptic surgical damage. Macrophages are key mediators of innate immunity that can display a pro-inflammatory M1 phenotype or an anti-inflammatory M2 phenotype. Erythropoietin (EPO) is a hematopoietic hormone that exerts anti-inflammatory effects by influencing macrophage function. We hypothesized that EPO would prevent POCD by promoting macrophage phenotype switching to the M2 phenotype post-surgery. To evaluate the effects of EPO on POCD and macrophage polarization post-surgery, we administered EPO (5,000 U/kg) with or without an arginase inhibitor (amino-6-boronohexanoic acid, 10 mg/kg) to ICR mice before and after abdominal surgery. Forty-eight hours post-surgery, we assessed memory, synapse function, and macrophage/microglial phenotypes in the spleen and hippocampus. We also investigated M1/M2 phenotypes in RAW264.7 and BV2 cells stimulated with lipopolysaccharide and interferon-γ (M1 inducers) in the presence or absence of EPO. EPO prevented POCD, decreased surgery-related synaptic dysfunction, and attenuated pro-inflammatory cytokine generation in the hippocampus. Moreover, EPO suppressed M1-related genes expression and promoted M2 genes expression in the spleen and hippocampus post-surgery. Furthermore, EPO decreased the proportions of macrophages/microglia expressing an M1 surface marker (CD40) and increased those expressing an M2 surface marker (CD206). Arginase inhibition abolished the beneficial effects of EPO on POCD. In vitro, EPO treatment promoted switching of RAW264.7 and BV2 cells stimulated with M1 inducers to an M2 phenotype. In conclusion, EPO prevents POCD by promoting macrophage phenotype switching toward the M2 phenotype.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2017 Tipo del documento: Article País de afiliación: Corea del Sur

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Front Pharmacol Año: 2017 Tipo del documento: Article País de afiliación: Corea del Sur